Tumor Biology

, Volume 37, Issue 5, pp 5761–5763 | Cite as

Letter regarding “MT1-MMP is not a good prognosticator of cancer survival: evidence from 11 studies” by Wu KP et al.

  • Chao Tu
  • Jianping Zhou
  • Lianwen Yuan


With great interest, we carefully read a meta-analysis entitled “MT1-MMP is not a good prognosticator of cancer survival: evidence from 11 studies” in Tumor Biology (by Wu KP et al.), in which the investigators aimed to assess the association between MT1-MMP expression and prognosis of patients with various types of cancers by calculating the pooled hazard ratio (HR) with corresponding 95 % confidence interval (95 % CI). They have reached an important conclusion that MT1-MMP overexpression indicated an unfavorable overall survival (OS) in cancers and the pooled HR (95 % CI) was 2.46 (95 % CI 1.75–3.47). In addition, subgroup analysis showed the HRs (95 % CI) were 3.73 (95 % CI 2.67–5.21) and 2.46 (95 % CI 1.69–3.59) for MT1-MMP in lung cancer and gastric cancer, respectively. Before these results can be accepted, we would like to address several concerns related to this meta-analysis.


Comments Cancer Gastric cancer Lung cancer MT1-MMP Meta-analysis 


Compliance with ethical standards

Conflicts of interest



  1. 1.
    Wu KP, Li Q, Lin FX, et al. MT1-MMP is not a good prognosticator of cancer survival: evidence from 11 studies. Tumour Biol. 2014;35(12):12489–95.CrossRefPubMedGoogle Scholar
  2. 2.
    Yoshizaki T, Maruyama Y, Sato H, et al. Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma. Int J Cancer. 2001;95(1):44–50.CrossRefPubMedGoogle Scholar
  3. 3.
    Massi D, Franchi A, Ketabchi S, et al. Expression and prognostic significance of matrix metalloproteinases and their tissue inhibitors in primary neuroendocrine carcinoma of the skin. Hum Pathol. 2003;34(1):80–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  1. 1.Department of Geriatric SurgeryThe Second Xiangya Hospital of Central South UniversityChangshaChina

Personalised recommendations